Pyc Therapeutics (Asx: Pyc)

Pyc Therapeutics (Asx: Pyc) company information, Employees & Contact Information

PYC Therapeutics (ASX: PYC) is a clinical stage biotechnology company pioneering a new generation of RNA therapeutics for genetic diseases. It works by combining two complementary platforms: RNA-based drug design and PYC’s proprietary drug delivery technology. PYC's library of naturally derived cell penetrating peptides provide its delivery platform to overcome the major challenges of RNA therapeutics - getting into the target cell. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including two programs focused on inherited eye diseases and preclinical discovery efforts focused on neurodegenerative diseases. PYC’s discovery and laboratory operations are located in Australia, and the Company’s preclinical and clinical operations are based in San Fransisco California.
Looking for a particular Pyc Therapeutics (Asx: Pyc) employee's phone or email?

Pyc Therapeutics (Asx: Pyc) Questions

News

PYC Therapeutics Establishing New U.S. Headquarters in San Diego, Announces Residency at Johnson & Johnson Innovation, JLABS - PR Newswire

PYC Therapeutics Establishing New U.S. Headquarters in San Diego, Announces Residency at Johnson & Johnson Innovation, JLABS PR Newswire

PYC Therapeutics to Host Quarterly Investor Call on April 15th 8:00am AWST | 10am AEST - Troy Record

PYC Therapeutics to Host Quarterly Investor Call on April 15th 8:00am AWST | 10am AEST Troy Record

PYC Therapeutics Highlights Progress in Its Transformation to a U.S. Clinical-Stage Company and 2021 Corporate Objectives - PR Newswire

PYC Therapeutics Highlights Progress in Its Transformation to a U.S. Clinical-Stage Company and 2021 Corporate Objectives PR Newswire

PYC Therapeutics - businessnews.com.au

PYC Therapeutics businessnews.com.au

PYC Therapeutics Highlights Continued Progress of Ocular and CNS Pipeline Programs and U.S. Expansion in First Quarter Update - Troy Record

PYC Therapeutics Highlights Continued Progress of Ocular and CNS Pipeline Programs and U.S. Expansion in First Quarter Update Troy Record

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - A First for Any RP11 Treatment To-Date - PR Newswire

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - A First for Any RP11 Treatment To-Date PR Newswire

PYC Therapeutics Announces Preclinical Data Demonstrating Superior PPMO Delivery to the Brain - PR Newswire

PYC Therapeutics Announces Preclinical Data Demonstrating Superior PPMO Delivery to the Brain PR Newswire

Top Pyc Therapeutics (Asx: Pyc) Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant